Expertise in
8
conditions

Bruno Moulin

Strasbourg, FR 
Expertise in
8
conditions
Strasbourg, FR 

Overview

Bruno Moulin practices practicing medicine in Strasbourg, France.

Mr. Moulin is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Membranoproliferative Glomerulonephritis, Chronic Kidney Disease, Glomerulonephritis, Kidney Transplant, and Hepato-Pancreato-Biliary Surgery.

He is actively involved in clinical research, co-authoring 142 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

Strasbourg, France
Other Locations
Bas-et-lezat, France
CHRU Nancy, 4 Rue Du Morvan, Nancy, 54500, France
Amiens, France
Paris, France
Poitiers, France
Dialysis and Renal Transplantation
Besancon, 25000, France
Boulogne-billancourt, France
CHU Reims
Reims, France
CHU Tours
Tours, France
Caen, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease: a Prospective, Multicenter, Randomized, Open-label, Clinical Trial
Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease: a Prospective, Multicenter, Randomized, Open-label, Clinical Trial
Enrollment Status: Active_not_recruiting
Publish Date: March 20, 2026
Intervention Type: Other, Drug
Study Phase: Phase 3
Double-blind Placebo-Controlled Randomized Clinical Trial of Mineralocorticoid Receptor Blockade With Eplerenone After Renal Transplantation : Effect on Graft Function at 3 Months.
Double-blind Placebo-Controlled Randomized Clinical Trial of Mineralocorticoid Receptor Blockade With Eplerenone After Renal Transplantation : Effect on Graft Function at 3 Months.
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2023
Intervention Type: Drug
Study Drug: Eplerenone
Study Phase: Phase 3
Interest of Systematic Transplantectomy Versus Conventional Care After Kidney Graft Failure
Interest of Systematic Transplantectomy Versus Conventional Care After Kidney Graft Failure
Enrollment Status: Completed
Publish Date: November 21, 2022
Intervention Type: Procedure
Study Phase: Not Applicable
Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Enrollment Status: Completed
Publish Date: December 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
Clinical Study of a Single Ciliopathy: Alström Syndrome
Clinical Study of a Single Ciliopathy: Alström Syndrome
Enrollment Status: Terminated
Publish Date: June 21, 2019
A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican®) and Reduced Dose of Cyclosporine A (Neoral®) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic®) and Standard Dose of Cyclosporine A (Neoral®).
A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican®) and Reduced Dose of Cyclosporine A (Neoral®) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic®) and Standard Dose of Cyclosporine A (Neoral®).
Enrollment Status: Completed
Publish Date: November 14, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 5 Less Clinical Trials

142 Total Publications

Optimizing ADAMTS13 prophylaxis to reduce relapse and organ failure in congenital thrombotic thrombocytopenic purpura.
Optimizing ADAMTS13 prophylaxis to reduce relapse and organ failure in congenital thrombotic thrombocytopenic purpura.
Journal: Blood advances
Published: July 01, 2025

Frequently Asked Questions about Bruno Moulin

Is Bruno Moulin a top-rated expert for Kidney Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Bruno Moulin is classified as an Elite expert for Kidney Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Bruno Moulin participate in research or clinical trials?

Yes. Bruno Moulin has published 142 articles and abstracts on conditions like Kidney Transplant. You can view a list of Bruno Moulin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Moulin's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 39 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile